DNA damage can be referred to as any adverse alteration, which may occur in the form of base additions, base deletions or break in the sister DNA strands. Damage of genetic material is known to interfere with essential cellular processes, such as transcription and DNA replication. DNA lesions at specific positions have been shown to be associated with the induction of heritable mutations. The accumulation of such erroneous elements in the genetic code may ultimately result in cellular aberrations, compromising structure, function, and viability. Such adverse alterations may also form the genetic basis of a variety of diseases. In fact, chromosomal aberrations and germline mutations often lead to the loss of function of tumor suppressor genes and / or those coding for essential cell cycle checkpoint proteins, which may result in uncontrollable cellular proliferation and thereby, the development of disease indications, such as cancer.
To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis.com/reports/dna-damage-response-targeting-therapeutics-market.html
Researchers have estimated the total number of DNA damaging events per cell, per day, to be around 60,000. Further extrapolations suggest that there are about 3×1017 DNA damaging events taking place, per hour, in the human body. However, in eukaryotes, the likely adverse events / health implications associated with DNA damage are largely prevented by a robust DNA repair system.
To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/dna-damage-response-targeting-therapeutics-market/free-insights.html
§ DNA Damage Repair (DDR): This system involves a coordinated sequence of events, involving the detection of DNA damage points (by sensor proteins), followed by the transduction of information ataxia-telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) and the subsequent repair of damaged DNA segments.
For more information please click on the following link: - https://www.rootsanalysis.com/reports/dna-damage-response-targeting-therapeutics-market.html
Other Recent Offerings
1. TIL-based Therapies Market, 2021-2030
2. TCR-based Therapies Market, 2021-2030
3. Peptide Therapeutics Market, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
The applications of oligonucleotides are vast, even beyond the life science / pharma sector; however, owing to complexities associated with the synthesis and processing of these molecules, such operations are usually outsourced to capable CMOs Roots Analysis is pleased to announce the publication of its recent study, titled, “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030.” The report features an extensive study of the current scenario and future potential of the custom synthesis, modification and purification services market for oligonucleotides, which are intended for research, diagnostic, and therapeutic applications.
The study includes in-depth analyses, highlighting the capabilities of service providers engaged in this domain.
In addition to other elements, it includes:A detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications.A competitiveness analysis of prominent oligonucleotide manufacturers, featuring insightful pictorial summaries and representations.Elaborate profiles of key players that offer a diverse range of capabilities for custom synthesis, modification and purification of oligonucleotides.An analysis of the various partnerships pertaining to oligonucleotide manufacturing, which have been established in the recent past.An analysis of the various expansion initiatives undertaken by service providers engaged in this domain.A detailed analysis of completed, ongoing and planned clinical research studies of various oligonucleotide-based drug products.An estimate of the overall, annual capacity for manufacturing oligonucleotides based on data reported by industry stakeholders in the public domain.An informed estimate of the annual clinical and commercial demand for oligonucleotides.A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing custom synthesis, modification and purification services for oligonucleotides.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) To request for customize report – https://www.rootsanalysis.com/reports/304/request-customization.html Type of ManufacturingCustom ManufacturingLarge-scale ManufacturingType of Oligonucleotides ManufacturedAntisense OligonucleotidesmiRNAsshRNAssiRNAsOther OligonucleotidesScale of OperationClinicalCommercialPurpose of ProductionIn-houseOutsourcedTarget Therapeutic AreaAutoimmune DisordersCardiovascular DisordersGenetic DisordersInfectious DiseasesMetabolic DisordersNeuromuscular DisordersOncological DisordersOphthalmic DisordersOther Therapeutic AreasSize of manufacturerSmallMid-sizedLargeKey Geographical Region North AmericaEuropeAsia-Pacific and Rest of the WorldTo request for sample report – https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/request-sample.html Transcripts of interviews held with the following senior level representatives of stakeholder companiesJoachim Bertram (Chief Scientific Officer and Managing Director, IBA Lifesciences)Tobias Pohlmann (Founder and Managing Director, BianoScience) Key companies covered in the reportAgilent TechnologiesAjinomoto Bio-Pharma ServicesBioSpringCordenPharmaIntegrated DNA TechnologiesKaneka EurogentecLGC Biosearch TechnologiesMicrosynthNitto Denko AveciaSigma AldrichThermo Fisher ScientificTrilink Biotechnologies For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html Other Recent OfferingsChina Biopharmaceutical Contract Manufacturing Market, 2020-2030Pharmaceutical Continuous Manufacturing Market, 2020-2030Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.
The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected] - https://www.facebook.com/RootsAnalysisLinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/Twitter - https://twitter.com/RootsAnalysis
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
The global creatinine measurement market size is expected to reach USD 841.01 million by 2028 at a CAGR of 8.3%, according to the latest report by Reports and Data.
The market revenue growth is attributed to rising prevalence of renal disorders, especially in developing countries, and rising awareness regarding preventive healthcare approaches globally.
Creatinine is basically a synthesized blood chemical waste product, which passes through kidneys to be filtered and gets eliminated through urine.
Key companies operating in the global market and profiled in the report include: Hoffmann-la Roche ltd. (Switzerland), Danaher Corporation (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific (U.S.), Randox Laboratories (UK), Siemens Healthineers (Germany), Pointe Scientific (U.S.), Diasys Diagnostic Systems GmbH (Germany), Diazyme Laboratories (U.S.), Sentinel Ch.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/4052Further key findings in the reportJaffe’s kinetic method segment is expected to register largest revenue share in the creatinine measurement market during the forecast period, due to its ability of creatinine measurement in a wide range of clinical samples.
Hospitals segment is predicted to occupy fastest revenue CAGR in the global market going ahead.
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
